Treace Medical Concepts Maintains Buy Rating with $12 Price Target: Analyst

Lake Street analyst Ben Haynor maintains a Buy rating for Treace Medical Concepts (TMCI) with a $12.00 price target, despite the company's shares closing at $5.68. Haynor has an average return of -18.6% and a 26.14% success rate on recommended stocks. The overall analyst consensus rating for TMCI is Moderate Buy with an average price target of $9.58, a 68.66% upside from current levels.

Treace Medical Concepts (TMCI) reported its second-quarter earnings on August 7, with a loss of $0.28 per share, slightly better than the expected loss of $0.29. This represents a 3.45% positive surprise compared to the Zacks Consensus Estimate [1]. The company's revenue for the quarter ended June 2025 was $47.39 million, surpassing the Zacks Consensus Estimate by 0.79% [1]. This marks the fourth consecutive quarter where TMCI has exceeded consensus revenue estimates.

The company's stock price responded positively to the earnings report, rising 3.84% in after-hours trading to close at $5.68 [2]. Analysts at InvestingPro have given the company a "FAIR" overall financial health score, noting strong relative value metrics [2]. The company's adjusted EBITDA loss improved by 58% to $3.6 million, reflecting operational efficiencies and new product launches [2].

Treace Medical Concepts anticipates full-year 2025 revenue between $224 million and $230 million, representing a 7-10% growth. The company expects to achieve breakeven adjusted EBITDA and foresees a significant revenue increase in Q4 2025, driven by new product launches and market expansion [2].

Analysts maintain a mixed outlook for TMCI. Lake Street analyst Ben Haynor maintains a Buy rating with a $12.00 price target, despite the company's shares closing at $5.68. The overall analyst consensus rating for TMCI is Moderate Buy with an average price target of $9.58, a 68.66% upside from current levels [1].

Investors should be mindful of the industry outlook, as the Medical - Instruments sector is currently in the bottom 41% of the 250 plus Zacks industries [1]. Another company in the same industry, Hyperfine, Inc. (HYPR), is expected to report a quarterly loss of $0.12 per share in its upcoming report, representing a year-over-year change of +14.3% [1].

References:
[1] https://www.nasdaq.com/articles/treace-medical-concepts-tmci-reports-q2-loss-beats-revenue-estimates
[2] https://www.investing.com/news/transcripts/earnings-call-transcript-treace-medical-q2-2025-beats-eps-forecast-stock-rises-93CH-4179281